M Zankel

1.4k total citations · 1 hit paper
12 papers, 1.0k citations indexed

About

M Zankel is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, M Zankel has authored 12 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 10 papers in Epidemiology and 2 papers in Immunology. Recurrent topics in M Zankel's work include Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (8 papers) and Hepatitis B Virus Studies (7 papers). M Zankel is often cited by papers focused on Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (8 papers) and Hepatitis B Virus Studies (7 papers). M Zankel collaborates with scholars based in Germany, Italy and United States. M Zankel's co-authors include Michael P. Manns, Julika Mayer, Teresa Santantonio, Heiner Wedemeyer, Giuseppe Pastore, Markus Cornberg, Christian Trautwein, Manfred Dietrich, Elmar Jaeckel and C Fischer and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

M Zankel

11 papers receiving 975 citations

Hit Papers

Treatment of Acute Hepatitis C with Interferon Alfa-2b 2001 2026 2009 2017 2001 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Zankel Germany 6 929 914 95 48 48 12 1.0k
Minoru Horikita Japan 5 743 0.8× 713 0.8× 83 0.9× 47 1.0× 30 0.6× 6 787
J.M. Sánchez‐Tapias Spain 13 725 0.8× 638 0.7× 68 0.7× 97 2.0× 17 0.4× 20 772
Olivier Lada France 16 1.3k 1.3× 1.3k 1.4× 218 2.3× 38 0.8× 55 1.1× 37 1.4k
E. Chiaberge Italy 8 848 0.9× 857 0.9× 97 1.0× 35 0.7× 35 0.7× 22 922
D. Cavalletto Italy 11 732 0.8× 700 0.8× 55 0.6× 78 1.6× 35 0.7× 19 815
S Yotsumoto Japan 5 1.1k 1.2× 1.1k 1.2× 141 1.5× 56 1.2× 37 0.8× 6 1.2k
Françoise Darthuy France 13 727 0.8× 651 0.7× 84 0.9× 96 2.0× 27 0.6× 17 793
Jocelyne Rémiré France 12 693 0.7× 614 0.7× 79 0.8× 96 2.0× 26 0.5× 17 750
Maria Grazia Ruvoletto Italy 6 437 0.5× 461 0.5× 54 0.6× 22 0.5× 41 0.9× 9 552
Uta Naumann Germany 12 575 0.6× 578 0.6× 70 0.7× 17 0.4× 30 0.6× 32 680

Countries citing papers authored by M Zankel

Since Specialization
Citations

This map shows the geographic impact of M Zankel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Zankel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Zankel more than expected).

Fields of papers citing papers by M Zankel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Zankel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Zankel. The network helps show where M Zankel may publish in the future.

Co-authorship network of co-authors of M Zankel

This figure shows the co-authorship network connecting the top 25 collaborators of M Zankel. A scholar is included among the top collaborators of M Zankel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Zankel. M Zankel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Berg, Thomas, V Weich, G Teuber, et al.. (2009). Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients†‡. Hepatology. 50(2). 369–377. 41 indexed citations
2.
Lütgehetmann, Marc, Tassilo Volz, Alexander Quaas, et al.. (2008). Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication. Antiviral Therapy. 13(1). 57–66. 60 indexed citations
4.
Lütgehetmann, Marc, Karsten Wursthorn, Peter Buggisch, et al.. (2006). 508 48 Weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvement. Journal of Hepatology. 44. S189–S189. 1 indexed citations
5.
Wursthorn, Karsten, Marc Lütgehetmann, Maura Dandri, et al.. (2006). Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 44(3). 675–684. 354 indexed citations
8.
Teuber, G, M. Pascu, Thomas Berg, et al.. (2003). Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. Journal of Hepatology. 39(4). 606–613. 34 indexed citations
11.
Jaeckel, Elmar, Markus Cornberg, Heiner Wedemeyer, et al.. (2001). Treatment of Acute Hepatitis C with Interferon Alfa-2b. New England Journal of Medicine. 345(20). 1452–1457. 516 indexed citations breakdown →
12.
Jaeckel, Elmar, Markus Cornberg, T. Santantonio, et al.. (2001). Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection. Gastroenterology. 120(5). A567–A567. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026